Detalhe da pesquisa
1.
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
Br J Dermatol
; 190(5): 668-679, 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38226713
2.
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
J Eur Acad Dermatol Venereol
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38451052
3.
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Dermatol Ther (Heidelb)
; 12(2): 495-510, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35025062